目的 比较皮下免疫治疗何舌下免疫治疗对哮喘患儿免疫应答功能影响的差异。方法 收集尘螨致敏哮喘患儿86例,分为舌下免疫治疗组(SLIT组,n=29)、皮下免疫治疗组(SCIT组,n=13)、结束皮下免疫治疗足疗程组(结束SCIT组,n=14)以及常规药物治疗组(对照组,n=30)。体外水平检测各组患儿外周血单个核细胞经螨蛋白浸液刺激后CD4+ T淋巴细胞中调节性T淋巴细胞比例(Treg%)的变化;比较SCIT组和SLIT组患儿治疗前、治疗后6个月、治疗后12个月体液免疫学指标和临床疗效指标变化的差异。结果 未给予抗原刺激时,SCIT组患儿CD4+ T细胞中Treg%显著高于SLIT组、对照组;给予抗原刺激后的4组CD4+ T细胞中Treg%均显著性降低。在免疫治疗后6个月和12个月,SCIT组患儿其血清sIgE和sIgG4水平与治疗前相比差异均有统计学意义,而SLIT组患儿仅血清sIgE水平与治疗前相比差异有统计学意义,sIgG4水平未见随时间变化而变化。结论 不同免疫治疗途径在引发哮喘患儿内在免疫学应答反应上存在时间差异性,其中SCIT免疫治疗患儿免疫应答反应出现的时间更早。
Abstract
Objective To compare the difference in the effects of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) on immunological responses in children with asthma. Methods A total of 86 children with asthma caused by dust mites were enrolled and divided into a SLIT group (n=29), a SCIT group (n=13), a group receiving complete SCIT course (complete SCIT group; n=14), and a group receiving conventional medication (control group, n=30). Peripheral blood mononuclear cells were isolated and stimulated with house dust mite extract for 48 hours in vitro, and the percentage of regulatory T cells (Treg%) in CD4+ T cells was measured by flow cytometry. Analysis of variance with repeated measures was applied to compare the changes in humoral immunological indices and therapeutic effects in the SCIT and SLIT groups before treatment and after 6 and 12 months of treatment. Results Before antigenic stimulation, Treg% in CD4+ T cells in the SCIT group was significantly higher than that in the SLIT and control groups; after antigenic stimulation was given, Treg% in the four groups decreased significantly. After 6 and 12 months of immunotherapy, the SCIT group had significant changes in serum sIgE and sIgG4 levels, while the SLIT group only showed a significant change in serum sIgE level. Conclusions Temporal difference exists in different immunotherapies to cause immunological responses in children with asthma, and immunological responses induced by SCIT may occur earlier.
关键词
支气管哮喘 /
调节性T细胞 /
皮下免疫治疗 /
舌下免疫治疗 /
儿童
Key words
Bronchial asthma /
Regulatory T cell /
Sublingual immunotherapy /
Subcutaneous immunotherapy /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Lambrecht BN, Hammad H. The immunology of asthma[J]. Nat Immunol, 2015, 16(1): 123-127.
[2] 全国儿童哮喘防治协作组. 中国城区儿童哮喘患病率调查[J]. 中华儿科杂志, 2003, 41(2): 47-51.
[3] 全国儿科哮喘协作组. 2000年与1990年儿童支气管哮喘患病率的调查比较[J]. 中华结核和呼吸杂志, 2004, 27(2): 112-116.
[4] 全国儿科哮喘协作组. 中国疾病预防控制中心环境与健康相关产品安全所. 第三次中国城市儿童哮喘流行病学调查[J]. 中华儿科杂志, 2013, 51(10): 729-735.
[5] Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization American academy of allergy, asthma and immunology[J]. Ann Allergy Asthma Immunol, 1998, 81(5 pt 1): 401-405.
[6] Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience[J]. Curr Opin Otolaryngol Head Neck Surg, 2014, 22(3): 208-210.
[7] Steinke JW, Lawrence MG. T-cell biology in immunotherapy[J]. Ann Allergy Asthma Immunol, 2014, 112(3): 195-199.
[8] 中华医学会儿科学会呼吸学组, 编辑委员会中华儿科杂志. 儿童支气管哮喘诊断与防治指南[J]. 中华儿科杂志, 2008,46(10): 745-753.
[9] Brozek JL, Bousquet J, Baena-Caqnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3): 466-476.
[10] Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma[J]. Allergy, 2011, 66(2): 178-185.
[11] 陈伯亚, 龙自铭, 黄燕君, 等. 舌下含服粉尘螨滴剂治疗单一和多重过敏变应性鼻炎患者的临床疗效评估[J]. 中华耳鼻咽喉头颈外科杂志, 2013, 48(7): 549-554.
[12] Canoniea GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunothempy for respiratory allergy. A statement of a World Allergy Organization (WAO) task force[J]. Allergy, 2007, 62(3): 317-324.
[13] Casale TB, Canoniea GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials[J]. J Allergy Clin Immunol, 2009, 124(4): 665-670.
[14] 中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎特异性免疫治疗专家共识[J].中华耳鼻咽喉头颈外科杂志, 2011,46(12): 976-980.
[15] Jutel M, Akdis M, Blaser K, et al. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more[J]. Allergy, 2006, 61(7): 796-807.
[16] Akdis CA, Blaser K, Akdis M. Mechanisms of allergen-specific immunotherapy[J]. Chem Immunol Allergy, 2006, 91: 195-203.
[17] Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy[J]. Curr Allergy Asthma Rep, 2014, 14(11): 473.
[18] Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases[J]. Curr Opin Pharmacol, 2014, 17: 30-37.
[19] Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials [J]. Am J Respir Crit Care Med, 1995, 151(4): 969-974.
[20] Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review [J]. Allergy, 1999, 54(10): 1022-1041.
[21] Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma[J]. Cochrane Database Syst Rev, 2000, (2): CD001186.
[22] Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma[J]. Cochrane Database Syst Rev, 2003, (4): CD001186.
[23] Calamita Z, Saconato H, Pelá AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method [J]. Allergy, 2006, 61(10): 1162-1172.
[24] Antúnez C, Mayorga C, Corzo JL, et al. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration[J]. Pediatr Allergy Immunol, 2008, 19(3): 210-218.
[25] Durham SR, Walker SM, Varga EM, et al. Long term clinical efficacy of grass-pollen immunotherapy[J]. N Engl J Med, 1999, 341(7): 468-475.
[26] Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper[J]. J Allergy Clin Immunol, 1998, 102(4 Pt 1): 558-562.
基金
国家自然科学基金(81441001); 北京市科技专项(Z131100006813044)。
PDF(1528 KB)
